Evaluation of the Oral Iron Chelator 1,2‐Dimethyl‐3‐hydroxypyrid‐4‐one (L1) in Iron‐Loaded Patients

Annals of the New York Academy of Sciences

Volumn 612, Issue 1, 1990, Pages 369-377

  OLIVIERI, NANCY F ^a   TEMPLETON, DOUGLAS M ^b   KOREN, GIDEON ^a   CHUNG, DEREK ^a   HERMANN, CHRISTINE ^a   FREEDMAN, MELVIN H ^a   McCLELLAND, ROBERT A ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE;

CLINICAL ARTICLE; CONFERENCE PAPER; HUMAN; IRON CHELATION; IRON OVERLOAD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; BLOOD TRANSFUSION; DEFEROXAMINE; HUMAN; IRON; IRON CHELATING AGENTS; PYRIDONES; SUPPORT, NON-U.S. GOV'T; THALASSEMIA;

EID: 0025563292     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1990.tb24324.x     Document Type: Article

References (32)

1. Management of iron overload in the pediatric patient
2. Cardiac disease free survival in patients with thalassemia major treated with subcutaneous deferoxamine: An update of the Toronto cohort
3. Improvement in iron status and liver function in patients with transfusional iron overload with long‐term subcutaneous desferrioxamine
4. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload
5. Depletion of excessive liver iron stores with desferrioxamine
6. Survival and desferrioxamine in thalassemia major
7. Long‐term chelation therapy in thalassemia major: Effect on liver iron concentration, liver histology, and clinical progress
8. Growth and sexual maturation in thalassemia major
9. High dose deferoxamine and Diamond‐Blackfan anemia
10. Desferrioxamine to improve cardiac function in iron overloaded patients with thalassemia major
11. Continuous high‐dose intravenous desferrioxamine treatment for iron overload
12. A non‐human primate model for the study of oral iron chelators
13. Iron chelating therapy. 1988
14. 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one, an orally active chelator for treatment of iron overload
15. Effective chelation of iron in thalassemia with the oral chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one
16. Synthetic chelating agents in iron metabolism
17. Chelation therapy in thalassemia major: A one‐year double blind study of 2,3‐dihydroxy‐benzoic acid
18. The relationship between lipophilicity of hydroxypyrid‐4‐one iron chelators and cellular iron mobilization, using an hepatocyte culture model
19. Evaluation in vivo of hydroxypyrid‐4‐one iron chelators intended for the treatment of iron overload by the oral route
20. Orally active α‐ketohydroxy pyridine iron chelators intended for clinical use: In vivo studies in rabbits
21. In vivo evaluation of hydroxypyridone iron chelators in a mouse model
22. Ferrioxamine excretion in iron loaded man
23. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
24. Simple synthesis of the potent iron chelators 1‐alkyl‐3‐hydroxy‐2‐methylpyrid‐4‐ones
25. Diet for patients with a short bowel: High fat or high carbohydrate
26. Minimum sample preparation for the determination of 10 elements in pig feces and feeds by atomic absorption spectrophotometry and a spectrophotometric procedure for total phosphorus
27. A new HPLC method for the measurement of deferoxamine in body fluids
28. Total iron balance in response to desferrioxamine
29. Intravenous desferrioxamine and total iron balance
30. Animal toxicology of iron chelator L1
31. Safety of oral iron chelator L1
32. Agranulocytosis and thrombocytopenia in patient with Blackfan‐Diamond anaemia during oral chelator L1